首页 » CD19 knockout Nalm6-luciferase NTCC®人B细胞前体急性淋巴细胞白血病细胞株cell line-BioVector NTCC细胞保藏中心

CD19 knockout Nalm6-luciferase NTCC®人B细胞前体急性淋巴细胞白血病细胞株cell line-BioVector NTCC细胞保藏中心

  • 价  格:¥1998950
  • 货  号:NTCC®CD19 knockout Nalm6-luciferase
  • 产  地:北京
点击询问我要采购
 竭诚为您服务!
BioVector NTCC典型培养物保藏中心
联系人:Dr.Xu, Biovector NTCC Inc.

电话:400-800-2947 工作QQ:1843439339 (微信同号)

邮件:Biovector@163.com

手机:18901268599

地址:北京

已注册
 

CD19 knockout Nalm6-luciferase NTCC®人B细胞前体急性淋巴细胞白血病细胞株human B-cell precursor acute lymphoblastic leukemia (ALL) cell line

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心


The NTCC® CD19 knockout Nalm6-luciferase cell line is a valuable tool for research in immunology and oncology. Here's a breakdown of its key features and significance:

Key Features:

  • Nalm6 Origin: Derived from the Nalm6 cell line, a human B-cell precursor acute lymphoblastic leukemia (ALL) cell line.

  • CD19 Knockout: The CD19 gene, which encodes a protein essential for B-cell development and function, has been genetically removed using CRISPR/Cas9 technology.

  • Luciferase Expression: The cell line constitutively expresses firefly luciferase, allowing for non-invasive monitoring of cell growth and proliferation using bioluminescence imaging techniques.

Significance in Research:

  1. Studying CD19 Function: The CD19 knockout enables researchers to investigate the role of CD19 in B-cell development, signaling pathways, and immune responses.

  2. Cancer Research:

    • Modeling B-cell Malignancies: The cell line can serve as a model for B-cell malignancies, such as B-ALL, that express CD19.

    • Evaluating CD19-Targeted Therapies: The CD19 knockout can be used to assess the efficacy of CD19-targeted therapies, such as chimeric antigen receptor (CAR) T-cell therapies, which are revolutionizing cancer treatment.


  3. Drug Discovery: The cell line can be used to screen for new drugs that target B-cell malignancies or modulate B-cell function.

Applications:

  • Immunology Research: Studying B-cell development, differentiation, and function.

  • Oncology Research: Investigating B-cell malignancies, evaluating CD19-targeted therapies, and screening for new anticancer drugs.

  • Drug Discovery: Identifying and developing novel therapeutic agents for B-cell-related diseases.

Note:

  • The use of this cell line requires appropriate safety measures in the laboratory, as it involves working with genetically modified organisms.

  • The characteristics and behavior of the CD19 knockout Nalm6-luciferase cell line can be influenced by various factors, such as culture conditions and the presence of other cells or factors in the environment.

Image

Nalm6-Fluc-Puro/CD19-KO - Imanis Life Sciences | United States

Firefly Luciferase CD19 Knockout NALM6 Cell Line 82168

生产厂家Supplier:

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail:BioVector@163.com


http://www.biovector.net


您正在向 biovector.net  发送关于产品 CD19 knockout Nalm6-luciferase NTCC®人B细胞前体急性淋巴细胞白血病细胞株cell line-BioVector NTCC细胞保藏中心 的询问

点击“立即发送”后,我们将在1个工作日内与您取得联系。